Androgen receptors beyond prostate cancer: an old marker as a new target
Metrics: PDF 2111 views | HTML 3037 views | ?
Javier Munoz1,*, Jennifer J. Wheler2,* and Razelle Kurzrock3
1 Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona
2 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas
3 Center for Personalized Cancer Therapy, Division and Hematology and Oncology, Moores Cancer Center, The University of California San Diego, La Jolla, California
* These authors share first authorship
Jennifer J. Wheler, email:
Keywords: androgen receptor, therapy, molecular abnormalities, phase I clinical trials
Received: October 16, 2014 Accepted: November 14, 2014 Published: November 15, 2014
Androgen receptors (ARs) play a critical role in the development of prostate cancer. Targeting ARs results in important salutary effects in this malignancy. Despite mounting evidence that ARs also participate in the pathogenesis and/or progression of diverse tumors, exploring the impact of hormonal manipulation of these receptors has not been widely pursued beyond prostate cancer. This review describes patterns of AR expression in a spectrum of cancers, and the potential to exploit this knowledge in the clinical therapeutic setting.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.